| |
Mean ± SD
|
N
|
|---|
|
Age (years)
|
63.5 ± 6.5
|
98
|
|
Prostatic volume (c.c)
|
44.4 ± 22.4
|
98
|
|
Testosterone (nmol/L)
|
13.9 ± 4.9
|
98
|
|
Total PSA (ng/mL)
|
9.7 ± 8.20
|
98
|
| | |
N (%)
|
|---|
|
BMI (kg/m2)
|
< 25
|
21 (21.7)
|
|
25–29.99
|
50 (51.6)
|
|
≥ 30
|
26 (26.7)
|
|
Total PSA (µg/L)
|
< 4
|
7 (7.2)
|
|
4–10
|
60 (61.9)
|
|
> 10
|
30 (30,9)
|
|
ISUP GG
|
|
Low risk
|
Group I
|
38 (38,8)
|
|
Group II
|
24 (24,5)
|
|
High risk
|
Group III
|
19 (19.3)
|
|
Group IV
|
10 (10.2)
|
|
Group V
|
7 (7.2)
|
|
T pathological stage
|
≤ T2a
|
69 (70.4)
|
|
T3, T4
|
29 (29,6)
|
|
No pathological stage
|
NX
|
53 (55.8)
|
|
N0
|
36 (37.9)
|
|
N1
|
6 (6.3)
|
- N number of patients, SD standard deviation, BMI body mass index, ISUP GG ISUP Grade Groups based on the Gleason score as follows: (Gleason score ≤ 6 group I; 3 + 4=7 group II; 4 + 3=7 group III; 4 + 4=8 group IV; and 9–10 group V); T-stage tumor category; N lymph node category
